MBX Biosciences (MBX) vs Prestige Consumer Healthcare (PBH)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
MBX Biosciences (MBX) has outperformed Prestige Consumer Healthcare (PBH) over the past year, gaining 83.0% versus a loss of 16.5%. MBX Biosciences is the larger company by market cap ($2.46 billion vs $2.35 billion), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | MBX | PBH |
|---|---|---|
| Share price | $49.55 | $49.63 |
| Market cap | $2.46B | $2.35B |
| 1-day change | -7.23% | +0.06% |
| YTD return | +57.10% | -19.55% |
| 1-year return | +82.98% | -16.48% |
| 5-year return | — | -12.02% |
| P/E ratio (TTM) | — | 15.32 |
| Forward P/E | — | 9.76 |
| EPS (TTM) | $-3.03 | $3.24 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $1.09B |
| Revenue growth (YoY) | — | -4.31% |
| Net income (latest FY) | $-87.00M | $190.30M |
| Gross margin | — | 54.71% |
| Operating margin | — | 28.42% |
| Net margin | — | 17.48% |
| 52-week high | $72.64 | $71.07 |
| 52-week low | $26.14 | $41.77 |
| Distance from 52-week high | -31.79% | -30.17% |
| Analyst consensus | strong_buy | buy |
| Avg. price target upside | +91.91% | +33.39% |
| Average volume | 532.80K | 583.25K |
| Shares outstanding | 49.66M | 47.40M |
| Employees | 63 | 890 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- MBX has outperformed PBH by 99.5 percentage points over the past year.
About MBX Biosciences
MBX stock →MBX Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision peptide therapies for the treatment of endocrine and metabolic disorders. Its lead product candidate is Canvuparatide (MBX 2109), a parathyroid hormone peptide prodrug, which is in Phase 3 clinical trial for the treatment of chronic hypoparathyroidism.
Health Care · Biotechnology: Pharmaceutical Preparations · 63 employees
About Prestige Consumer Healthcare
PBH stock →Prestige Consumer Healthcare Inc., together with its subsidiaries, develops, manufactures, markets, distributes, and sells over the counter (OTC) health and personal care products in North America, Australia, and internationally. It operates in two segments, North American OTC Healthcare and International OTC Healthcare.
Health Care · Biotechnology: Pharmaceutical Preparations · 890 employees
MBX vs PBH FAQ
Which is bigger, MBX Biosciences or Prestige Consumer Healthcare?
MBX Biosciences (MBX) is larger, with a market capitalization of $2.46B compared with $2.35B for Prestige Consumer Healthcare (PBH).
Which stock has performed better over the past year, MBX or PBH?
MBX returned +82.98% over the past 12 months, compared with -16.48% for PBH (price return, excluding dividends). Past performance does not predict future results.
Are MBX Biosciences and Prestige Consumer Healthcare in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.